Skip to main content
Top

18-12-2017 | Breast cancer | Article

IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients

Journal: Cancer Immunology, Immunotherapy

Authors: Narmeen Ahmad, Aula Ammar, Sarah J. Storr, Andrew R. Green, Emad Rakha, Ian O. Ellis, Stewart G. Martin

Publisher: Springer Berlin Heidelberg

Abstract

Macrophage-associated cytokines play an important role in cancer metastasis; however, the functions of interleukins (IL) 6 and 10 in breast cancer (BC) progression and metastasis are not clear. In this study the roles of IL-6/IL-10 in regulating vascular invasion and their prognostic significance in BC are investigated. MDA-MB-231 and MCF-7 migration (± IL-6 or IL-10) was assessed by scratch wound assay. Cancer cell adhesion to IL-6/IL-10 stimulated blood and lymphatic endothelial cells (EC) was investigated. Expression of IL-6 /IL-10 was assessed using immunohistochemistry in an annotated cohort of early stage BC (n = 1380) and associations with clinicopathological variables and clinical outcome evaluated. IL-6 did not alter BC cell migration however a dose-dependent inhibition in MDA-MB-231 migration with IL-10 treatment was observed (P = 0.03). BC cells were more adhesive to blood vs lymphatic EC, however, IL-6/IL-10 had no effect on adhesion patterns. High expression of IL-6/IL-10 was associated with clinicopathological criteria (e.g. hormone receptor status, all P < 0.05), improved disease-free survival (DFS; P < 0.05) and improved BC-specific survival (BCSS; only IL-6, P = 0.017). However, neither IL-6 nor IL-10 expression were independent prognostic factors from multivariate analysis. In BC subgroups, IL-6 and IL-10 were good prognosticators in terms of DFS in non-basal, non-triple-negative (non-TN), ER-positive, PgR-positive (only IL-10), and Her-2-negative (only IL-6) BC (all P < 0.05). IL-6 was associated with improved BCSS in non-basal, ER-positive and non-TN BC (all P < 0.05).
Literature
1.
Mohammed RA, Ellis IO, Elsheikh S, Paish EC, Martin SG (2009) Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications. Breast Cancer Res Treat 113(2):261–273. https://​doi.​org/​10.​1007/​s10549-008-9936-1 CrossRefPubMed
2.
Mohammed RA, Menon S, Martin SG, Green AR, Paish EC, Ellis IO (2014) Prognostic significance of lymphatic invasion in lymph node-positive breast carcinoma: findings from a large case series with long-term follow-up using immunohistochemical endothelial marker. Mod Pathol 27(12):1568–1577. https://​doi.​org/​10.​1038/​modpathol.​2014.​60 CrossRefPubMed
3.
Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC (2012) The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 107(5):864–873. https://​doi.​org/​10.​1038/​bjc.​2012.​347 CrossRefPubMedPubMedCentral
4.
Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 84(3):623–630. https://​doi.​org/​10.​1189/​jlb.​1107762 CrossRefPubMedPubMedCentral
5.
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899. https://​doi.​org/​10.​1016/​j.​cell.​2010.​01.​025 CrossRefPubMedPubMedCentral
6.
Ásgeirsson KS, Ólafsdóttir K, Jónasson JG, Ögmundsdóttir HM (1998) The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine 10(9):720–728CrossRefPubMed
7.
Chung YC, Chaen YL, Hsu CP (2006) Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res 26(5B):3905–3911PubMed
8.
Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirstrom K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17(18):6083–6096. https://​doi.​org/​10.​1158/​1078-0432.​CCR-11-0945 CrossRefPubMedPubMedCentral
9.
Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G, Culig Z (2000) Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 191(3):239–244CrossRefPubMed
10.
Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A (2000) Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer 88(9):2061–2071CrossRefPubMed
11.
Qu Z, Sun F, Zhou J, Li L, Shapiro SD, Xiao G (2015) Interleukin-6 prevents the Initiation but enhances the progression of lung cancer. Cancer Res 75(16):3209–3215. https://​doi.​org/​10.​1158/​0008-5472.​CAN-14-3042 CrossRefPubMedPubMedCentral
12.
Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen M, Albino AP, Bander NH (1993) Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 55(1):96–101CrossRefPubMed
13.
Heckel MC, Wolfson A, Slachta CA, Schwarting R, Salgame P, Katsetos CD, Platsoucas CD (2011) Human breast tumor cells express IL-10 and IL-12p40 transcripts and proteins, but do not produce IL-12p70. Cell Immunol 266(2):143–153. https://​doi.​org/​10.​1016/​j.​cellimm.​2010.​09.​010 CrossRefPubMed
14.
Itakura E, Huang RR, Wen DR, Paul E, Wunsch PH, Cochran AJ (2011) IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol 24(6):801–809. https://​doi.​org/​10.​1038/​modpathol.​2011.​5 CrossRefPubMedPubMedCentral
15.
Rabinovich A, Medina L, Piura B, Huleihel M (2010) Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw 21(2):122–128. https://​doi.​org/​10.​1684/​ecn.​2010.​0188 PubMed
16.
Kruger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Huls C, Blankenstein T, Diamantstein T (1994) Expression of interleukin 10 in human melanoma. Br J Cancer 70(6):1182–1185CrossRefPubMedPubMedCentral
17.
Wolk K, Kunz S, Asadullah K, Sabat R (2002) Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 168(11):5397–5402CrossRefPubMed
18.
Dennis KL, Blatner NR, Gounari F, Khazaie K (2013) Current status of interleukin-10 and regulatory T cells in cancer. Curr Opin Oncol 25(6):637–645. https://​doi.​org/​10.​1097/​CCO.​0000000000000006​ CrossRefPubMedPubMedCentral
19.
Sakamoto T, Saito H, Tatebe S, Tsujitani S, Ozaki M, Ito H, Ikeguchi M (2006) Interleukin-10 expression significantly correlates with minor CD8 + T cell infiltration and high microvessel density in patients with gastric cancer. Int J Cancer 118(8):1909–1914. https://​doi.​org/​10.​1002/​ijc.​21598 CrossRefPubMed
20.
Braun DA, Fribourg M, Sealfon SC (2013) Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation. J Biol Chem 288(5):2986–2993. https://​doi.​org/​10.​1074/​jbc.​M112.​386573 CrossRefPubMed
21.
Nisato RE, Harrison JA, Buser R, Orci L, Rinsch C, Montesano R, Dupraz P, Pepper MS (2004) Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span. Am J Pathol 165(1):11–24. https://​doi.​org/​10.​1016/​S0002-9440(10)63271-3 CrossRefPubMedPubMedCentral
22.
Safuan S, Storr SJ, Patel PM, Martin SG (2012) A comparative study of adhesion of melanoma and breast cancer cells to blood and lymphatic endothelium. Lymphat Res Biol 10(4):173–181. https://​doi.​org/​10.​1089/​lrb.​2012.​0007 CrossRefPubMedPubMedCentral
23.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4):387–391. https://​doi.​org/​10.​1038/​sj.​bjc.​6602678 CrossRefPubMedPubMedCentral
24.
Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR (2011) Tumor-infiltrating CD8 + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29(15):1949–1955. https://​doi.​org/​10.​1200/​JCO.​2010.​30.​5037 CrossRefPubMed
25.
Storr SJ, Zhang S, Perren T, Lansdown M, Fatayer H, Sharma N, Gahlaut R, Shaaban A, Martin SG (2016) The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. Oncotarget 7(30):47927–47937. https://​doi.​org/​10.​18632/​oncotarget.​10066 CrossRefPubMedPubMedCentral
26.
Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252–7259. https://​doi.​org/​10.​1158/​1078-0432.​CCR-04-0713 CrossRefPubMed
27.
Aleskandarany MA, Agarwal D, Negm OH, Ball G, Elmouna A, Ashankyty I, Nuglozeh E, Fazaludeen MF, Diez-Rodriguez M, Nolan CC, Tighe PJ, Green AR, Ellis IO, Rakha EA (2016) The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. Breast Cancer Res Treat 156(1):9–20. https://​doi.​org/​10.​1007/​s10549-016-3709-z CrossRefPubMed
28.
Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302–2310. https://​doi.​org/​10.​1158/​1078-0432.​CCR-08-2132 CrossRefPubMed
29.
Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, Lazennec G (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9(1):R15. https://​doi.​org/​10.​1186/​bcr1648 CrossRefPubMedPubMedCentral
30.
Fontanini G, Campani D, Roncella M, Cecchetti D, Calvo S, Toniolo A, Basolo F (1999) Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma. Br J Cancer 80(3–4):579–584. https://​doi.​org/​10.​1038/​sj.​bjc.​6690394 CrossRefPubMedPubMedCentral
31.
Llanes-Fernandez L, Alvarez-Goyanes RI, Arango-Prado Mdel C, Alcocer-Gonzalez JM, Mojarrieta JC, Perez XE, Lopez MO, Odio SF, Camacho-Rodriguez R, Guerra-Yi ME, Madrid-Marina V, Tamez-Guerra R, Rodriguez-Padilla C (2006) Relationship between IL-10 and tumor markers in breast cancer patients. Breast 15(4):482–489. https://​doi.​org/​10.​1016/​j.​breast.​2005.​09.​012 CrossRefPubMed
32.
Toiyama Y, Miki C, Inoue Y, Minobe S, Urano H, Kusunoki M (2010) Loss of tissue expression of interleukin-10 promotes the disease progression of colorectal carcinoma. Surg Today 40(1):46–53. https://​doi.​org/​10.​1007/​s00595-009-4016-7 CrossRefPubMed
33.
Fernandez-Garcia B, Eiro N, Miranda MA, Cid S, Gonzalez LO, Dominguez F, Vizoso FJ (2016) Prognostic significance of inflammatory factors expression by stroma from breast carcinomas. Carcinogenesis 37(8):768–776. https://​doi.​org/​10.​1093/​carcin/​bgw062 CrossRefPubMed
34.
Arihiro K, Oda H, Kaneko M, Inai K (2000) Cytokines facilitate chemotactic motility of breast carcinoma cells. Breast Cancer 7(3):221–230CrossRefPubMed
35.
Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, Cotari J, Alpaugh ML, de Stanchina E, Manova K, Li M, Bonafe M, Ceccarelli C, Taffurelli M, Santini D, Altan-Bonnet G, Kaplan R, Norton L, Nishimoto N, Huszar D, Lyden D, Bromberg J (2013) The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 15(7):848–862CrossRefPubMedPubMedCentral
36.
Čačev T, Radošević S, Križanac Š, Kapitanović S (2008) Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 29(8):1572–1580CrossRefPubMed
37.
Kundu N, Beaty TL, Jackson MJ, Fulton AM (1996) Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 88(8):536–541CrossRefPubMed
38.
Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J, Sheppard C, Hong K, Cutler C, Turner S, LaFace D, Kleinschek M, Judo M, Ayanoglu G, Langowski J, Gu D, Paporello B, Murphy E, Sriram V, Naravula S, Desai B, Medicherla S, Seghezzi W, McClanahan T, Cannon-Carlson S, Beebe AM, Oft M (2011) IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 20(6):781–796. https://​doi.​org/​10.​1016/​j.​ccr.​2011.​11.​003 CrossRefPubMed
39.
Wang S, Gao X, Shen G, Wang W, Li J, Zhao J, Wei YQ, Edwards CK (2016) Interleukin-10 deficiency impairs regulatory T cell-derived neuropilin-1 functions and promotes Th1 and Th17 immunity. Sci Rep 6:24249. https://​doi.​org/​10.​1038/​srep24249 CrossRefPubMedPubMedCentral
40.
Huber S, Gagliani N, Esplugues E, O’Connor W Jr, Huber FJ, Chaudhry A, Kamanaka M, Kobayashi Y, Booth CJ, Rudensky AY, Roncarolo MG, Battaglia M, Flavell RA (2011) Th17 cells express interleukin-10 receptor and are controlled by Foxp3(−) and Foxp3 + regulatory CD4 + T cells in an interleukin-10-dependent manner. Immunity 34(4):554–565. https://​doi.​org/​10.​1016/​j.​immuni.​2011.​01.​020 CrossRefPubMedPubMedCentral
41.
Eiro N, Gonzalez L, Gonzalez LO, Fernandez-Garcia B, Lamelas ML, Marin L, Gonzalez-Reyes S, del Casar JM, Vizoso FJ (2012) Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development. PLoS ONE 7(11):e49047. https://​doi.​org/​10.​1371/​journal.​pone.​0049047 CrossRefPubMedPubMedCentral
42.
ten Kate M, Hofland LJ, van Koetsveld PM, Jeekel J, van Eijck CH (2006) Pro-inflammatory cytokines affect pancreatic carcinoma cell. Endothel Cell Interact JOP 7(5):454–464
43.
Li Y, Yu H, Jiao S, Yang J (2014) Prognostic value of IL-10 expression in tumor tissues of breast cancer patients. Xi bao yu fen zi mian yi xue za zhi 30(5):517–520 (article Chinese)PubMed
44.
Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T (2000) Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 11(7):815–819CrossRefPubMed
45.
Yamamoto T, Matsuda T, Junicho A, Kishi H, Saatcioglu F, Muraguchi A (2000) Cross-talk between signal transducer and activator of transcription 3 and estrogen receptor signaling. FEBS Lett 486(2):143–148CrossRefPubMed